You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib

  • Technology appraisal guidance
  • Reference number: TA427
  • Published:  11 January 2017
  • Guidance
  • Tools and resources
  • Information for the public
  • History

On this page

  1. Expected publication
  2. Final appraisal determination
  3. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 223 KB)

    Published:
    11 January 2017

Final appraisal determination

  • Final appraisal determination

  • Committee papers (PDF 20.74 MB)

    Published:
    23 November 2016
  • Committee papers committee presentation (PDF 752 KB)

    Published:
    23 November 2016
  • Final appraisal determination document (PDF 467 KB)

    Published:
    23 November 2016

Invitation to participate

  • Final scope (PDF 109 KB)

    Published:
    19 May 2016
  • Final matrix (PDF 97 KB)

    Published:
    19 May 2016
  • NICE's response to comments on the draft scope and provisional matrix (PDF 179 KB)

    Published:
    19 May 2016
  • Equality impact assessment (Scoping) (PDF 64 KB)

    Published:
    19 May 2016
Back to top